ArticleHuman vaccines & immunotherapeutics2026
The importance of first-void urine for assessing HPV-specific antibodies: A comparison with midstream urine.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Humoral immunity to HPV is typically assessed via serum, which reflects systemic immune responses. However, local sampling may offer a more accurate representation of immunity at the site of infection. First-void urine (FVU), a self-collectible cervicovaginal sample, presents a non-invasive alternative. The difference in HPV-specific IgG concentrations between FVU and the subsequent midstream urine fraction, however, has not yet been systematically evaluated. In this proof-of-concept study, we examined the HPV16-specific IgG concentrations in paired FVU and midstream urine (MSU) samples collected from 19 healthy female volunteers using two FVU collection devices (10 mL and 20 mL). Antibody detection rates were significantly higher in FVU (89-95% for 10 and 20 mL devices, respectively) compared to MSU (53-58% for MSU collected after the 10 and 20 mL FVU collection, respectively), with no significant difference between the two FVU volumes. These findings highlight the critical importance of capturing the initial urine stream, for optimal detection of female genital tract-derived antibodies in urine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.